Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

Furanylfentanyl. ANNEX 1. Technical report on N-phenyl-N- [1-(2-phenylethyl)piperidin-4-yl]furan- 2-carboxamide (furanylfentanyl).

Brandt, SD, Elliott, S, Valur Danielsson, H, Almeida, A, Gallegos, A, Jorge, R, Christie, R, Evans-Brown, M and Sedefov, R (2017) Furanylfentanyl. ANNEX 1. Technical report on N-phenyl-N- [1-(2-phenylethyl)piperidin-4-yl]furan- 2-carboxamide (furanylfentanyl). Technical Report. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg.

EMCDDA_Furanylfentanyl_TR_final_layout.pdf - Published Version

Download (477kB) | Preview


This publication presents the data and findings of the risk assessment on furanylfentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. The Risk Assessment Report, which was submitted to the European Commission and the Council of the European Union on 23 May 2017, examines the health and social risks of the drug, information on international trafficking and the involvement of organised crime, as well as a consideration of the potential implications of subjecting the drug to control measures. Furanylfentanyl is the fourteenth new psychoactive substance to be risk assessed under the terms of Council Decision 2005/387/JHA. On the basis of the Risk Assessment Report - and on the initiative of the European Commission - on 15 November 2017, the Council decided that furanylfentanyl should be subject to control measures across the Member States. This decision was adopted in the final stage of the three-step process - early warning, risk assessment and control of new psychoactive substances - established by the Council Decision 2005/387/JHA. This legal framework allows the EU institutions and Member States to act on all new and potentially threatening narcotic and psychotropic drugs which appear on the European drug scene, with the EMCDDA and Europol, in collaboration with their respective networks playing a central role in the early detection of such substances as well as the harms caused by their use - information that underpins risk assessment, and, ultimately, decision-making.

Item Type: Monograph (Technical Report)
Subjects: Q Science > QD Chemistry
R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: European Monitoring Centre for Drugs and Drug Addiction
Date Deposited: 02 Jan 2018 12:30
Last Modified: 21 Jan 2022 15:35
DOI or ID number: 10.2810/716236
URI: https://researchonline.ljmu.ac.uk/id/eprint/7769
View Item View Item